The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia

Cancer

Volumn 79, Issue 1, 1997, Pages 104-109

  Stephan, Carsten ^a   Lein, Michael ^a   Jung, Klaus ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

benign prostate hyperplasia; diagnostic validity; prostate carcinoma; prostate specific antigen; prostate volume; ratio of free to total prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TUMOR VOLUME;

EID: 0031026385     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970101)79:1<104::AID-CNCR15>3.0.CO;2-8     Document Type: Article

References (27)

1. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
2. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
3. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787-94.
4. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
6. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
7. Lilja H. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with cellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest 1995;55(Suppl 220):47-56.
8. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
9. Prestigiacomo A, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995;55(Suppl 221):32-4.
10. Filella X, Alcover J, Molina R, Gimenez N, Rodriguez A, Jo J, et al. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer 1995;63:780-4.
11. Björk T, Hulkko S, Bjartell A, di Sant'Agnese A, Abrahamsson PA, Lilja H. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43:427-34.
12. Bjartell A, Björk T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of the human prostate epithelium. Urology 1993;42:502-10.
13. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
14. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992;20(Suppl 4):129-38.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
16. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55(Suppl 222):43-60.
17. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996;42:1026-33.
18. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
19. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102:S31-7.
20. Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995;153:111-4.
21. Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994;152:1510-4.
22. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-8.
23. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60-6.
24. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer 1996;78:337-40.
25. Catalona WJ, Smith DS. Free serum prostate-specific antigen and screening for prostate cancer. JAMA 1996;275:838.
26. Bangma CH, Kranse R, Schröder FH. Free serum prostate-specific antigen and screening for prostate cancer. JAMA 1996;275:837-8.
27. Spitz J, Benz P, Jauch M, Eiffler E, Köllermann M. Critical aspects related to the interpretation of the ratio free/total PSA, estimated by different assay methods. Anticancer Res 1995;15:2400-1.